AGORAPHOBIC AVOIDANCE, ANXIETY SENSITIVITY, AND EMOTIONAL DISTRESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A NARRATIVE REVIEW OF BIDIRECTIONAL MECHANISMS AND CLINICAL IMPLICATIONS
Main Article Content
Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition frequently complicated by significant psychological comorbidities, including anxiety disorders and panic-spectrum symptoms. Prevalence rates of anxiety and panic disorder in COPD patients substantially exceed those in the general population, contributing to diminished quality of life, increased exacerbation frequency, greater perceived dyspnea severity, prolonged hospitalizations, and elevated healthcare utilization. This narrative review synthesizes evidence on the interplay among agoraphobic avoidance, anxiety sensitivity (particularly its physical concerns dimension), catastrophic misinterpretations of bodily sensations, and emotional distress in COPD. Key findings indicate that agoraphobic avoidance—manifesting as evasion of physical exertion, public spaces, or situations perceived as escape-restrictive—operates not merely as a consequence of dyspnea-related fear or panic but as a maintaining factor. Bidirectional relationships emerge: elevated anxiety sensitivity and emotional distress predict avoidance behaviors, while avoidance perpetuates catastrophic beliefs, interoceptive hypervigilance, physical deconditioning, and intensified psychological symptoms. These mechanisms align with cognitive-behavioral models of anxiety maintenance and have direct implications for integrating targeted psychological interventions—such as exposure-based strategies and cognitive restructuring—into standard COPD management, including pulmonary rehabilitation. Limitations of existing research and directions for future longitudinal and interventional studies are discussed.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
2.Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24(4):461–470.
3.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023 Report.
4.Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res. 2002;53(4):859–863.
5.Livermore N, Sharpe L, McKenzie D. Fear and avoidance of activities in chronic obstructive pulmonary disease: The role of pulmonary rehabilitation. J Psychosom Res. 2010;68(5):489–496.
6.Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: Current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S–56S.
7.McCracken LM, Keogh E. Acceptance, mindfulness, and values-based action in chronic illness. J Psychosom Res. 2009;66(4):325–334.
8.Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): A review. Nord J Psychiatry. 2004;58(1):65–70.
9.Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
10.Simon NM, Pollack MH, Tuby KS, Stern TA. Anxiety disorders and chronic obstructive pulmonary disease: Comorbidity and treatment implications. Psychosomatics. 2005;46(3):178–185.
11.Taylor S. Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety. Mahwah, NJ: Lawrence Erlbaum Associates; 1999.
12.Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, et al. Robust dimensions of anxiety sensitivity: Development and initial validation of the Anxiety Sensitivity Index-3. Psychol Assess. 2007;19(2):176–188.
13.Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain. 2000;85(3):317–332.
14.World Health Organization. Chronic obstructive pulmonary disease (COPD) fact sheet. 2023.
15.Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
16.Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale. Thorax. 1999;54(7):581–586.